Armistice Capital LLC Acquires 484,000 Shares of Intellia Therapeutics, Inc. $NTLA

Armistice Capital LLC raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 72.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,156,000 shares of the company’s stock after buying an additional 484,000 shares during the period. Armistice Capital LLC’s holdings in Intellia Therapeutics were worth $10,392,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Oppenheimer & Co. Inc. grew its position in shares of Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares during the last quarter. Comerica Bank grew its position in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. Interchange Capital Partners LLC grew its position in shares of Intellia Therapeutics by 9.7% in the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after purchasing an additional 1,030 shares during the last quarter. Benjamin Edwards Inc. grew its position in shares of Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Intellia Therapeutics by 8.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,250 shares of the company’s stock valued at $159,000 after purchasing an additional 1,333 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NTLA. reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Morgan Stanley upped their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research report on Monday, April 27th. Wells Fargo & Company upped their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 3rd. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Royal Bank Of Canada upped their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.46.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $15.20 on Thursday. The company has a market capitalization of $2.12 billion, a P/E ratio of -4.29 and a beta of 1.92. Intellia Therapeutics, Inc. has a 1 year low of $7.95 and a 1 year high of $28.25. The business’s 50 day simple moving average is $13.70 and its 200 day simple moving average is $12.46.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter in the prior year, the business posted ($1.10) earnings per share. On average, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.